Green Julie sold $32K of IVVD

Green Julie (Chief Human Resources Officer) sold 40,780 shares of Invivyd, Inc. (IVVD) at an average of $0.78 ($0.72–$0.84) across 2 trades over 2026-08-17 to 2026-08-18 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Green Julie
Published Aug 19, 2026, 12:10 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 19, 2026, 12:42 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$IVVD
Neutral
medium confidence
Mentioned
$IVVD
Relevance
2/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$IVVDNeutralLow
01

Why it matters

The newest concrete information is the disclosed sale size, execution window, and weighted-average price range. Because it is 10b5-1 and relatively small, it is more likely to be noise than a fundamental driver.

02

Market read

A modest 10b5-1 insider sale was disclosed, which may slightly pressure sentiment but is unlikely to change valuation without other news.

03

What to watch

The filing does not indicate any change in business outlook, guidance, or financing; without additional catalysts, the transaction is mostly a sentiment datapoint.

Relevance 2/10Novelty 4/10Timing: Filed 2026-08-18 after-hours; reflects sales executed 2026-08-17 to 2026-08-18.

Background

This is an SEC Form 4 insider transaction disclosure for Invivyd, Inc. (IVVD). The insider is the Chief Human Resources Officer, and the sale is explicitly tied to a pre-arranged Rule 10b5-1 plan.

Company-level read

Ticker impact

$IVVDNeutralMedium confidence
Context

Invivyd insider Green Julie (Chief Human Resources Officer) sold about $31.7K of IVVD shares via a 10b5-1 plan on 2026-08-17 to 2026-08-18.

Expected impact

Low likelihood of a sustained price move; any reaction is likely short-lived unless accompanied by other company-specific news.

Evidence & confidence

The filing is a Form 4 insider transaction with a stated pre-arranged 10b5-1 plan, which typically reduces interpretive weight versus discretionary selling. The dollar value is modest, so incremental impact should be limited absent corroborating fundamentals.

Market effects

No clear sector read-through from a single, small 10b5-1 insider sale.

None.

None.

Counterpoint

Traders may overreact to insider sales; 10b5-1 plans are often used to manage liquidity needs and reduce signaling risk.

Key entities

  • Invivyd, Inc.

    Company whose insider transaction was disclosed on Form 4.

  • Green Julie

    Chief Human Resources Officer who sold IVVD shares.

  • Rule 10b5-1 plan

    Pre-arranged plan that typically reduces interpretive weight of insider selling.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$IVVDMed

Invivyd Posts Wider Loss In Q3 As Operating Expenses Rise

Invivyd, Inc. (IVVD) reported a wider Q3 net loss of $33.47 million, up from $10.47 million YoY, due to higher operating expenses. Revenue rose 18% to $15.45 million. The company provided updates on its pipeline, including VYD2311 for COVID-19 and VMS063 for measles, and announced leadership changes. Cash reserves totaled $126.40 million.

$IVVDHigh

Invivyd Reports Third Quarter 2026 Financial Results and Recent

Invivyd, Inc. (IVVD) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Invivyd Reports Third Quarter 2026 Financial Results and Recent Business Highlights • DECLARATION Phase 3 clinical trial data on VYD2311 (ibramvibart) to be available imminently, per the Accelerated Approval analysis and regulatory submission plan previously communic

$IVVDMedAI 8/10

Invivyd presents preclinical data on measles antibody candidate

Invivyd (NASDAQ:IVVD) presented preclinical data for its measles antibody candidate VMS063 at IDWeek 2026, showing antiviral activity against measles virus variants. The company plans to scale up manufacturing for clinical development in 2027. There are currently no FDA-approved treatments for measles, with U.S. cases nearly double in 2026 compared to 2025, according to Invivyd.

$IVVDLow

Invivyd, Inc. (IVVD) Unveils Preclinical Data for Measles mAb VMS063

Invivyd, Inc. (IVVD) presented preclinical data for VMS063, a novel monoclonal antibody for measles, showing in vitro activity against contemporary virus variants. The company is scaling up production for clinical development in 2027. There are currently no FDA-approved treatments for measles, and the U.S. is experiencing a surge in cases.

$IVVDLowAI 8/10

More than 9 million U.S. children are estimated to lack measles protection. Lab tests found an antibody could fight measles.

Invivyd (Nasdaq: IVVD) presented preclinical data for VMS063, a monoclonal antibody candidate for measles treatment and prevention. VMS063 showed potent in vitro activity against measles virus variants. Invivyd plans to scale up production for clinical development in 2027. The U.S. is experiencing a record number of measles cases in 2026, with over 9 million children unprotected.